|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||370.25 - 381.25|
|52-week range||308.57 - 390.01|
|Beta (5Y monthly)||0.25|
|PE ratio (TTM)||20.97|
|Forward dividend & yield||9.78 (2.64%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
ZURICH (Reuters) -Swiss drugmaker Roche said on Thursday that strong demand for COVID-19 tests had helped it rebound from a weak start to the year, as it posted better-than-expected sales for the first half. However, the Basel-based company flagged an anticipated slowdown in demand for the tests, which have helped it fare better than some drugmakers as the number of routine hospital visits and demand for other medicines fell during the pandemic. "As expected, demand for COVID-19 tests peaked in the second quarter and is likely to decrease in the second half of the year (although this) depends on how the pandemic develops," Chief Executive Severin Schwan said on a call with reporters, adding that there were still significant uncertainties.